CMA fines drugmakers £260m for 10,000% price hike

The UK’s Competition and Markets Authority (CMA) has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.

Big Pharma

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

4 March 2019 The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

CMA fines drugmakers £260m for 10,000% price hike

More on this story

Editor's picks

Editor's picks

More features